Published 1 month ago • loading... • Updated 1 month ago

CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo

CREATE Medicines unveiled RetroT, an all-RNA gene integration system for T cells, emphasizing enhanced genomic safety and site-specific integration without double-strand DNA breaks, viral vectors, or DNA templates.
CREATE Medicines successfully inserted a CD19-CAR transgene into human T cells using RetroT, confirmed by sequencing to show precise integration with no detectable off-target effects, as per their study findings.
Robert Hofmeister, Chief Scientific Officer of CREATE Medicines, stated that RetroT enables durable gene insertion while allowing for scalable clinical applications with their targeted delivery platform.
The RetroT platform utilizes human LINE-1 machinery to improve genomic safety and precision in gene editing over traditional methods, reducing off-target effects and genotoxicity.

Insights by Ground AI

54 Articles

WBOC 16

+53 Reposted by 53 other sources

Center

CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo

All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety profile.Successful genetic delivery of CART constructs to T cells

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year